Objective-Lecithin:cholesterol acyltransferase (LCAT) is thought to be important in reverse cholesterol transport. However, its association with coronary heart disease (CHD) and sudden death is controversial. Approach and Results-We prospectively studied 1927 individuals from the general population. Serum concentrations of apolipoprotein A-I, A-II, B, C-II, C-III, E, and LCAT activity measured as a serum cholesterol esterification rate were evaluated. We documented 61 events of CHD and sudden death during 10.9 years of follow-up. After adjustment for age and sex, LCAT activity was significantly associated with the risk of CHD and sudden death (hazard ratio, 3.02; 95% confidence interval, 1.49−6.12; P=0.002). In multivariate analysis adjusted for age, sex, current smoking status, history of diabetes mellitus, body mass index, systolic blood pressure, serum total cholesterol, and serum high-density lipoprotein cholesterol concentrations, the hazard ratio of LCAT activity for the risk of CHD and sudden death remained significant (hazard ratio, 3.07; 95% confidence interval, 1.35−7.01; P=0.008). However, when it was analyzed for men and women separately, this association remained significant only in women. Conclusions-Increased LCAT activity measured as a serum cholesterol esterification rate was a risk for CHD and sudden death in a Japanese general population. (Arterioscler Thromb Vasc Biol. 2013;33:1098-1104.)
H igh-density lipoproteins (HDL) are thought to play a central role in reverse cholesterol transport (RCT), which is the uptake of cholesterol from peripheral tissues and its transport to the liver, 1 and many epidemiological studies have shown that a decreased concentration of HDL-cholesterol (HDL-C) is associated with an increased risk of coronary heart disease (CHD). 2 Lecithin:cholesterol acyltransferase (LCAT) associates with HDL, and to a lesser extent low-density lipoproteins. 3 LCAT hydrolyzes the 2-acyl group of phosphatidylcholine (lecithin), and then transfers and esterifies the fatty acids to the free 3-hydroxy group of cholesterol with apolipoprotein (apo) A-I as a cofactor, and generates cholesterol ester and lysophosphatidylcholine. 1 The mature HDL can then be taken up by the liver and are eventually excreted as cholesterol in the bile. Therefore, esterification of cholesterol by LCAT has been regarded as a key step in RCT. However, the precise role of LCAT in the pathogenesis of CHD is not yet understood.
Experiments with LCAT overexpression models [4] [5] [6] [7] [8] and LCAT knockout mice [9] [10] [11] have demonstrated both proatherogenic and antiatherogenic effects of LCAT, and these discrepancies have not yet been clearly explained. 12, 13 Patients with LCAT deficiency attributable to mutations in the LCAT gene develop severe HDL deficiency. However, they do not seem to be particularly prone to premature CHD, 14 and there are also conflicting results when evaluating atherosclerosis as carotid intima-media thickness in patients with LCAT deficiency. 15, 16 In clinical studies, LCAT activity was shown to be elevated in patients with metabolic syndrome and was also associated with increased carotid atherosclerosis, 17 whereas other studies reported decreased LCAT activity in patients with CHD. 18, 19 However, all these studies lacked a prospective design.
Recently, 2 prospective case-control studies of general populations have been reported. In a case-control analysis nested in the European Prospective Investigation of CancerNorfolk population study, Holleboom et al reported that plasma concentrations of LCAT mass did not differ between CHD cases and controls. 20 In contrast, in a community-based nested case-control study of men, Dullaart et al reported that the age-adjusted incidence of cardiovascular disease was significantly increased in subjects with higher LCAT activity measured by the exogenous substrate method. However, this relationship was not significant after adjustment for lipids. 21 Thus, the number of prospective studies in humans is still limited, and the results are controversial. 12 Here, we report that increased LCAT activity measured as a serum cholesterol esterification rate by the endogenous substrate method is significantly associated with a future risk of CHD and sudden death in a community-based cohort study.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Baseline characteristics of the study cohort are presented in Table 1 . Women had higher concentrations of total cholesterol (TC), HDL-C, and non-HDL-C than men (all tests for trend, P<0.001). Men had higher proportions of current smokers (P<0.001) and patients with a history of diabetes mellitus (P=0.03), a higher serum concentration of triglycerides (TG) (P<0.001), and a higher level of serum thiobarbituric acid reactive substances (TBARS) (P=0.001), than Women.
During the 19 866 person-years of follow-up (median followup period, 10.9 years), we documented 19 cases of myocardial infarction (15 in men and 4 in women); 12 cases of angina pectoris, coronary artery bypass, and angioplasty procedures (10 in men and 2 in women); and 30 cases of sudden deaths (13 in men and 17 in women). Thus, the total number of events was 61. Table 2 shows the baseline measurements for each variable stratified by LCAT activity tertiles. Body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, serum hemoglobin A1c levels, serum TC, non-HDL-C, TG, apoA-I, apoA-II, apoB, apoC-II, apoC-III, and apoE concentrations were all significantly increased in subjects with high LCAT activity (all tests for trend, P<0.001), whereas serum HDL-C and HDL 2 -C concentrations were significantly decreased in subjects with high LCAT activity (P<0.001 and P<0.001, respectively).
In age-and sex-adjusted analysis, increased levels of waist circumference, hemoglobin A1c, serum apoC-II, and serum LCAT activity were significantly associated with the increasing risk of CHD and sudden death. The hazard ratios (HRs) Values are expressed as mean±SD except triglycerides, which are given as the median (interquartile range). BMI indicates body mass index; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin:cholesterol acyltransferase activity; SBP, systolic blood pressure; TBARS, thiobarbituric acid reactive substances; and TC, total cholesterol. *P<0.05 is considered to indicate statistically significant differences between men and women.
were inversely correlated with LCAT activity (R=-0.278 and R=-0.326, respectively). Systolic blood pressure, diastolic blood pressure, hemoglobin A1c, HDL 3 -C, apoA-I, and TBARS levels were positively correlated with LCAT activity, but to a lesser extent. These results indicate that LCAT activity is closely correlated with dyslipidemia, particularly with metabolic syndrome that involves increased TG-rich apoBcontaining lipoprotein and low HDL-C concentrations. Table 4 shows the age-and sex-adjusted LCAT activity tertile analysis for the incidence of CHD and sudden death. Serum LCAT activity was significantly associated with the risk of CHD and sudden death in women (HR, 5. Table 4 , model 1. Furthermore, ApoB and TG concentrations were highly correlated with LCAT activity; both have previously been reported to be associated with a risk of CHD. 31 We therefore performed multivariate analysis, adjusting for the same variables as model 1, but substituting apoB and TG for TC and HDL-C (Table 4, 
Discussion
Our population-based cohort study demonstrated that increased serum LCAT activity expressed as a cholesterol esterification rate using the endogenous substrate method is associated with an increased risk of CHD and sudden death. This association is significant even after adjustment for established coronary risk factors, most of which are highly correlated with LCAT activity. Increased LCAT activity may therefore be an independent risk factor for CHD and sudden death in the general population. However, in sex-specific analyses, the association was significant in women, but not in men.
In the nested case-control study from the European Prospective Investigation of Cancer-Norfolk population study, Holleboom et al has reported a higher risk for CHD in women, but not men, with high LCAT mass concentrations. 20 This Values are expressed as mean±SD except triglycerides, apo-CII, apoC-III, and apoE, which are given as the median (interquartile range). Apo indicates apolipoprotein; BMI, body mass index; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin:cholesterol acyltransferase activity; SBP, systolic blood pressure; TBARS, thiobarbituric acid reactive substances; and TC, total cholesterol.
finding is in good agreement with our results. In addition, their method of measuring LCAT mass concentration is reported to have an excellent correlation with our method of measuring LCAT activity, 26 further supporting our results. The reason why the association between LCAT and CHD is higher in women than in men is not clear. Li et al recently reported that LCATdeficient female mice are protected from diet-induced obesity and insulin resistance in a sex-specific manner. 32 They found decreased endoplasmic reticulum stress markers and increased gene expressions which prevent adipogenesis, in hyperlipidemic LCAT-deficient female mice. They also reported that LCAT may cause metabolic disorders in association with hyperlipidemia. 11 Another possible explanation for this sexspecific effect may be because of the higher percentage of men who smoke. Albers et al has reported that higher smoking rates are associated with decreased LCAT mass; 33 thus, smoking may attenuate the effect of increased LCAT activity.
We defined LCAT activity in the present study, as the cholesterol esterification rate in the presence of endogenous plasma lipoproteins. The initial rate of cholesterol esterification has been supposed to represent HDL-C esterification. 3 However, plasma TG-rich lipoproteins such as very lowdensity lipoproteins (VLDL) have been reported to receive the majority of the cholesterol ester generated by the LCAT reaction, 34 and plasma VLDL and lipid transfer proteins have been known to affect cholesterol esterification in human plasma. 35, 36 Furthermore, previous studies have revealed that cholesterol esterification in incubated plasma is positively associated with increasing TG-rich lipoprotein concentrations using both the endogenous, [36] [37] [38] [39] and the exogenous substrate methods, 40 and is negatively associated with increasing HDL concentrations using the endogenous substrate methods. 36, 38, 39 Moreover, HDL 2 has been proposed as a competitive inhibitor of LCAT, 36, 37, 41, 42 whereas HDL 3 has been reported to be a favorable substrate for LCAT with the use of endogenous substrate method or the reconstituted model using purified LCAT and isolated lipoproteins. [41] [42] [43] It should be noted that genetically deficient LCAT individuals are different from individuals from the general population. The former are not able to produce sufficient LCAT enzymes. Therefore, they have the difficulty in cholesterol esterification reactions, leading to low plasma HDL-C levels. 15 In this situation, plasma HDL-C concentration may be positively correlated with plasma LCAT mass concentration and LCAT activity. However, individuals from the general population have sufficient potential to produce the enzyme, and most of them can also produce appropriate plasma HDL. The product HDL-C, particularly HDL 2 subfraction, is supposed to have potential to inhibit LCAT, whereas HDL 3 and smaller HDL can serve as substrates which facilitate LCAT reaction. 41, 42 These findings are consistent with our results showing that LCAT activity is highly correlated with increased serum concentrations of apoB, apoC-II, apoC-III, and apoE, all of which are components of TG-rich lipoproteins, and inversely correlated with serum HDL-C concentration, particularly HDL 2 -C concentration. Thus, our results indicate that elevated LCAT activity may reflect a dyslipidemic condition. Taken together, we can suggest a mechanistic explanation for the relationship between increased LCAT activities and CHD as follows: increased plasma TG-rich lipoprotein concentrations have been shown to be associated with low plasma HDL-C concentrations, 44 and both plasma LCAT activities and the cholesterol ester transfer from HDL to VLDL may also be facilitated by increasing TG-rich lipoprotein concentrations, 36 leading to high plasma apoB-containing lipoprotein cholesterol and low HDL-C concentrations. The apoB-containing lipoproteins can be removed by the receptor-mediated uptake in the liver as an alternative RCT pathway. However, as distinct from HDL, they are potentially atherogenic lipoproteins, and therefore may promote atherosclerosis. Thus, increased LCAT activity in association with hyperlipidemia may cause CHD.
Nevertheless, the underlying mechanism by which increased LCAT activity leads to the development of CHD and sudden death is not clear. Recently, our group 23 and others [45] [46] [47] have reported that increased oxidative stress and subsequent oxidative modification of lipids are risk factors for CHD. Furthermore, recent studies have shown that oxidative injury causes oxidation of not only LDL, 48 but also other lipoproteins, 49, 50 all of which contribute to atherosclerosis. LCAT has been reported to have antioxidant effects preventing low-density lipoprotein oxidation. 7, 51, 52 However, LCAT has also been reported to promote VLDL oxidation. 53 Furthermore, Ng et al has reported that LCAT deficiency may be rather favorable for reducing oxidative Correlations between LCAT activity and serum triglycerides, apoC-II, apoC-III, and apoE were calculated with the use of Spearman correlation coefficient, and other variables were calculated with the use of Pearson correlation coefficient. Apo indicates apolipoprotein; BMI, body mass index; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LCAT, lecithin:cholesterol acyltransferase activity; SBP, systolic blood pressure; TBARS, thiobarbituric acid reactive substances; and TC, total cholesterol. *R denotes the correlation coefficient for the corresponding P value.
stress in a hyperlipidemic mouse model. 11 We measured the serum level of TBARS as a marker of lipid peroxidation and found that it was significantly correlated with serum LCAT activity. This result may support the hypothesis that increased LCAT activity is related to increased oxidative stress on VLDL, as LCAT activity has been shown to be positively correlated with increasing VLDL concentration. 37, 38, 40, 54 However, both serum LCAT activity and serum TBARS level have also been reported to be correlated with serum lipids, 37, 38, 40, [54] [55] [56] making it difficult to conclude that increased TBARS level is a consequence of increased LCAT activity. In addition, lysophosphatidylcholine, generated by LCAT, has been reported to inhibit endothelium-dependent vascular relaxation, 57 promote monocyte recruitment to the vascular wall, 58 and reduce the beneficial effects of LCAT on the RCT pathway. 59 These deleterious effects of lysophosphatidylcholine generated by LCAT reaction may promote the development of CHD and sudden death. However, we did not evaluate serum lysophospholipid concentration in this study. Further studies are therefore needed to clarify the underlying mechanism by which an increased cholesterol esterification rate promotes CHD and sudden death.
LCAT has long been believed to play an important role in RCT. 1 However, recent studies have raised the question of this idea. Calabresi et al demonstrated, using LCAT deficient human serum, that functional LCAT is not required for macrophage cholesterol efflux, 60 or for efficient atheroprotection. 15 Tanigawa et al demonstrated that serum from LCAT-overexpressing mice has a reduced ability to promote cholesterol efflux from ex vivo macrophages via ATP-binding cassette transporter A1. 8 Moreover, Schwartz et al reported that HDL can deliver a considerable amount of unesterified cholesterol directly to the liver without LCAT-mediated conversion into cholesterol ester. 35, 61 These results suggest that the LCAT reaction may not be critical for RCT. 62 Increased LCAT activity may be the result of an increase in TG-rich lipoproteins, [36] [37] [38] 40, 54 and may therefore represent potentially impaired RCT. 8 Taken together, patients with metabolic disorders have increased LCAT activity, 17, 36, 38, 40 and may be at risk for impaired RCT, leading to CHD and sudden death.
Recent studies have advanced the concept of RCT, 63, 64 and measuring plasma HDL-C concentrations is no longer considered sufficient to estimate RCT in individuals. 65, 66 Although LCAT has been considered useful in evaluating RCT, our data clearly show that LCAT activity, measured as the serum cholesterol esterification rate, cannot be a suitable marker for RCT. Thus, to estimate the RCT pathway, we should consider another approach. 66 Our study has several limitations. First, we have measured initial rates of cholesterol esterification in serum, which is considered to take place in HDL. 3 However, we must consider that cholesterol esterification also takes place in other lipoproteins, such as VLDL and low-density lipoproteins. Second, we could not find any associations between lipid markers, other than apoCII, and the risk of CHD and sudden death. It is likely that lipid-modifying treatments during the follow-up period affected the incidence of CHD. To elucidate this, we mailed questionnaires to the participants whose serum total cholesterol concentrations were ≥220 mg/dL at baseline, asking them whether they had been prescribed lipid-modifying agents during the follow-up period. Most participants with hypercholesterolemia indeed received statin therapy after baseline study, probably attenuating the deleterious effects of hypercholesterolemia on the development of CHD and sudden death in this population (data not shown). In addition, we measured serum lipids and LCAT activities only once at the baseline and the follow-up period was >10 years, which may therefore lead to underestimation of the relationships between these variables and events. 67 Third, we could not evaluate the cause of the sex-specific effects of LCAT activity on CHD and sudden death. Further studies are needed to resolve these problems.
In conclusion, increased LCAT activity was associated with a future risk of CHD and sudden death in the general population. This association was significant in women, but not in men. Measuring the cholesterol esterification rate using the endogenous substrate method as a marker for LCAT activity is useful for predicting future CHD and sudden death. CHD indicates coronary heart disease; CI, confidence interval; and LCAT, lecithin:cholesterol acyltransferase activity.
*CHD includes fatal or nonfatal myocardial infarction, angina pectoris, and performance of coronary bypass surgery or angioplasty.
†HR indicates a hazard ratio for the tertile 3 subjects as compared with the tertile 1 subjects.
‡Multivariate model 1 includes covariates of age, sex, current smoking status, history of diabetes mellitus, body mass index, systolic blood pressure, serum total cholesterol, and serum high-density lipoprotein cholesterol levels.
§Multivariate model 2 includes covariates of age, sex, current smoking status, history of diabetes mellitus, body mass index, systolic blood pressure, serum apolipoprotein B, and serum triglyceride levels.
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